Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Richell Booijink,Leon W. M. M. Terstappen,Eshwari Dathathri,Khrystany Isebia,Jaco Kraan,John Martens,Ruchi Bansal
DOI: https://doi.org/10.1002/1878-0261.13653
2024-04-19
Molecular Oncology
Abstract:Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their role in cancer progression. Understanding cCAFs could lead to new treatment options for mPCa. In prostate cancer (PCa), cancer‐associated fibroblasts (CAFs) promote tumor progression, drug resistance, and metastasis. Although circulating tumor cells are studied as prognostic and diagnostic markers, little is known about other circulating cells and their association with PCa metastasis. Here, we explored the presence of circulating CAFs (cCAFs) in metastatic castration‐naïve prostate cancer (mCNPC) patients. cCAFs were stained with fibroblast activation protein (FAP), epithelial cell adhesion molecule (EpCAM), and receptor‐type tyrosine‐protein phosphatase C (CD45), then FAP+EpCAM− cCAFs were enumerated and sorted using fluorescence‐activated cell sorting. FAP+EpCAM− cCAFs ranged from 60 to 776 (389 mean ± 229 SD) per 2 × 108 mononuclear cells, whereas, in healthy donors, FAP+ EpCAM− cCAFs ranged from 0 to 71 (28 mean ± 22 SD). The mCNPC‐derived cCAFs showed positivity for vimentin and intracellular collagen‐I. They were viable and functional after sorting, as confirmed by single‐cell collagen‐I secretion after 48 h of culturing. Two cCAF subpopulations, FAP+CD45− and FAP+CD45+, were identified, both expressing collagen‐I and vimentin, but with distinctly different morphologies. Collectively, this study demonstrates the presence of functional and viable circulating CAFs in mCNPC patients, suggesting the role of these cells in prostate cancer.
oncology
What problem does this paper attempt to address?